NASDAQ:ARQT 30 December 2025

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Shares of Arcutis Biotherapeutics dropped 8.7% on Monday, slipping $2.46 to $25.76, following the company’s update on its 2026 priorities. The dermatology drugmaker set a $455 million to $470 million target for net product sales in its ZORYVE franchise. The stock hit a session low of $25.51 during trading.

12 January 2026

NASDAQ:ARQT·Pharmaceuticals·Stock Market

Arcutis stock sinks 5% after wild swing as traders eye Fed, FDA clock and earnings

Arcutis Biotherapeutics shares slid 5.3% to $28.29 in afternoon trading on Friday, after climbing as high as $30.70 earlier. The stock was last at the session low.

9 January 2026

Earnings Reports·Federal Reserve·NASDAQ:ARQT·Stock Market

Arcutis Biotherapeutics stock today: ARQT ends 2025 up 3.4% as traders eye FDA, earnings dates

With U.S. markets closed for New Year’s Day, shares of Arcutis Biotherapeutics Inc last closed up 3.42% at $29.04 in the final trading session of 2025. The stock ranged from $28.08 to $29.67 on volume of about 1.87 million shares. ARQT is up about 99% over the past year and has traded between $11.13 and $31.77 over the last 52 weeks. Investing.com

2 January 2026

Earnings Reports·NASDAQ:ARQT·Stock Market

Arcutis stock (ARQT) in focus after insider sale notice as U.S. markets shut for New Year’s Day

Arcutis Biotherapeutics shares are in focus after a regulatory filing showed an executive planned to sell a small block of stock, with U.S. markets closed on Thursday for New Year’s Day. The dermatology drugmaker last closed up 3.4% at $29.04 on Dec. 31. Intercontinental Exchange

1 January 2026

NASDAQ:ARQT·Stock Market

Arcutis Biotherapeutics stock pops today as ARQT bucks biotech dip into year-end trade

Shares of Arcutis Biotherapeutics Inc rose 3.8% to $29.16 by 10:33 a.m. ET on Wednesday, extending gains in the final U.S. trading session of 2025. The Nasdaq-listed dermatology drugmaker traded between $28.08 and $29.19, with about 181,000 shares changing hands.

31 December 2025

NASDAQ:ARQT·Pharmaceuticals·Stock Market

Arcutis Biotherapeutics stock slides today as biotech pulls back, ARQT down nearly 3%

Arcutis Biotherapeutics shares fell 2.9% to $27.74 in afternoon trading on Tuesday, after moving between $27.72 and $28.65. Volume was about 0.6 million shares.

30 December 2025

NASDAQ:ARQT·Stock Market

NASDAQ:ARQT 30 December 2025 - 12 January 2026

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Arcutis stock sinks 5% after wild swing as traders eye Fed, FDA clock and earnings

Arcutis Biotherapeutics stock today: ARQT ends 2025 up 3.4% as traders eye FDA, earnings dates

Arcutis stock (ARQT) in focus after insider sale notice as U.S. markets shut for New Year’s Day

Arcutis Biotherapeutics stock pops today as ARQT bucks biotech dip into year-end trade

Arcutis Biotherapeutics stock slides today as biotech pulls back, ARQT down nearly 3%

TechStock² Updates

Strategy Sells $653 Million in MSTR, Swells Cash Holdings Beyond Bitcoin Divestment

Costco Wholesale (NASDAQ:COST) Maintains Robust Sales as Wall Street’s $1,090 Price Target Relies on Further Multiple Expansion

Apple (NASDAQ:AAPL) Sheds About $97 Billion in Market Capitalization After Jefferies Cuts Rating

UnitedHealth (NYSE:UNH) Optum Health exceeds 2026 profit target, attention turns to 2027

Archer Aviation (NYSE:ACHR) Gains 11% Following Boeing Deal, Locks in $200 Million Revenue

Top Stock Picks

Taiwan Semiconductor

AerCap

Constellation Energy

Walt Disney

American International Group

Live updates

Investment Disclaimer